Cell: strong antibody 1-18 can limit the production of HIV resistance
-
Last Update: 2020-02-06
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
February 6, 2020 / Biovalley BIOON / - -- antiretroviral drugs (Art) is the gold standard for the treatment of HIV infection They are very effective in inhibiting the replication of the virus, but they need to be taken daily for a lifetime, which may have side effects In view of the high variability of HIV and its ability to adapt quickly, it is necessary to use at least two art drugs in combination to prevent drug resistance and treatment failure Broad neutralizing antibodies against HIV are the research focus of new treatment options for the treatment and prevention of HIV infection They work in a very different way from conventional art drugs, because they target the virus by specifically binding to HIV surface proteins Clinical trials have shown that broad neutralizing antibodies have the potential to reduce the viral load in the blood of HIV infected people However, similar to art drugs, the effect of single antibody is only temporary due to the production of virus resistance Now, in a new study, researchers from the University of Cologne in Germany and the California Institute of technology in the United States have identified a new antibody called 1-18 The antibody is powerful and resistant to 97% of tested HIV variants Therefore, 1-18 is one of the best broad neutralizing antibodies against HIV described so far The related research results were published online in the journal Cell on January 30, 2020, with the title of "restriction of HIV-1 escape by a highly broad and potent neutralizing antibody" The corresponding author is Dr Florian Klein of University of Cologne The first authors of this paper are Dr Philipp schommers, Dr Henning gr ü ll and Dr Morgan E Abernathy of Caltech Picture from cell, 2020, DOI: 10.1016/j.cell.2020.01.010 The researchers detailed the mechanism of action of antibodies 1-18 1-18 binds and inactivates a surface structure of HIV, which is of particular significance, after all, this surface structure is essential for the infection and replication of the virus Effective HIV therapy based on antibody 1-18 in a mouse model that can reproduce human HIV infection, the researchers studied the therapeutic efficacy of the newly identified antibody 1-18 In this model, other broad neutralizing antibodies show only short-term effects because HIV is rapidly resistant to them In contrast, treatment with antibodies 1-18 inhibited viral load and maintained this inhibition during treatment "These results indicate that HIV resistance to antibody 1-18 is limited compared to other antibodies," said gr ü LL Because of the powerful effect of antibody 1-18, these researchers think it is a promising candidate antibody for HIV immunotherapy Klein added, "in addition, antibody 1-18 has great potential to prevent HIV infection through passive immunization." Clinical trials are planned to further study antibody 1-18 (BIOON Com) reference: 1 Philipp schmmers et al Restriction of HIV-1 escape by a high broad and potent neutralising antibody Cell, 2020, DOI: 10.1016/j.cell.2020.01.010 2 High active HIV antibody restrictions development of virtual resistance https://mediaexpress.com/news/2020-01-high-hiv-antibody-restrictions-virtual.html
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.